CARTPT

Across TCGA pan-cancer cohorts, CARTPT Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CARTPT data layer compared with 20 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CARTPT Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CARTPT expression acts as an unfavorable survival marker.

OV, HNSC, and UCEC are the cancer types where CARTPT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.092	0.541	<.001	18	view →
HNSC	OS	Median	II,III,IV	0.179	0.671	.041	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CARTPT–OV (DFS)

Open the OV breakdown →